Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -35.48M | -34.20M | -35.76M | -32.14M | -31.48M |
| Total Depreciation and Amortization | 39.00K | 35.00K | 28.00K | 18.00K | 9.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.94M | 3.18M | 3.04M | 3.08M | 3.15M |
| Change in Net Operating Assets | 1.76M | 1.27M | 2.06M | -1.12M | -392.00K |
| Cash from Operations | -30.75M | -29.71M | -30.63M | -30.17M | -28.71M |
| Capital Expenditure | -37.00K | -23.00K | -94.00K | -94.00K | -88.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.96M | 1.00K | 10.10M | 135.00K | 135.00K |
| Cash from Investing | -35.99M | -22.00K | 10.01M | 41.00K | 47.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 53.01M | 223.00K | 25.02M | 25.02M | 25.02M |
| Repurchase of Common Stock | -35.00K | -45.00K | -62.00K | -76.00K | -60.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.12M | -273.00K | -272.00K | -272.00K | -272.00K |
| Cash from Financing | 51.86M | -95.00K | 24.68M | 24.67M | 24.68M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.88M | -29.82M | 4.06M | -5.46M | -3.98M |